ADMA Biologics, Inc.
ADMA
$21.68
-$0.652-2.92%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 65.15% | 63.39% | 58.69% | 55.69% | 67.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.15% | 63.39% | 58.69% | 55.69% | 67.59% |
| Cost of Revenue | 23.76% | 19.19% | 16.40% | 26.74% | 40.70% |
| Gross Profit | 141.16% | 162.94% | 170.70% | 136.17% | 158.17% |
| SG&A Expenses | 25.22% | 4.92% | -5.39% | -8.68% | -10.97% |
| Depreciation & Amortization | -46.41% | -23.13% | -2.00% | 3.20% | 1.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.96% | 13.81% | 8.34% | 13.92% | 20.85% |
| Operating Income | 468.86% | 8,679.78% | 620.61% | 285.57% | 162.07% |
| Income Before Tax | 545.16% | 421.36% | 197.22% | 93.60% | 57.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 799.98% | 398.48% | 186.34% | 92.36% | 57.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 799.98% | 398.48% | 186.34% | 92.36% | 57.15% |
| EBIT | 468.86% | 8,679.78% | 620.61% | 285.57% | 162.07% |
| EBITDA | 348.75% | 1,225.20% | 1,189.05% | 411.55% | 201.56% |
| EPS Basic | 768.86% | 368.92% | 176.25% | 92.61% | 62.31% |
| Normalized Basic EPS | 24,150.00% | 507.99% | 251.52% | 147.77% | 100.75% |
| EPS Diluted | 727.08% | 349.91% | 168.72% | 91.06% | 61.61% |
| Normalized Diluted EPS | 27,091.67% | 492.63% | 246.85% | 146.55% | 100.64% |
| Average Basic Shares Outstanding | 4.07% | 5.63% | 8.14% | 10.44% | 13.19% |
| Average Diluted Shares Outstanding | 7.18% | 7.73% | 11.20% | 12.40% | 14.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |